Candel Therapeutics, Inc.
For the period ended Jun 30, 2026. Filed Aug 13, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 13, 2026
CADL$9.35-1.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Stockholders’ Equity (Unaudited)
Condensed Consolidated Statements of Stockholders’ Equity
(In thousands, except share amounts)
| COMMON STOCK · TREASURY STOCK · ADDITIONALPAID-IN · ACCUMULATED · STOCKHOLDERS’ | |||||||
|---|---|---|---|---|---|---|---|
| SHARES | AMOUNT | SHARES | AMOUNT | CAPITAL | DEFICIT | EQUITY | |
| Balance, December 31, 2025 | 55,020,911 | $550 | (122,608) | $(448) | $282,207 | $(230,387) | $51,922 |
| Options exercised | 32,455 | — | — | — | 59 | — | 59 |
| Stock-based compensation | — | — | — | — | 3,589 | — | 3,589 |
| Change in fair value of NC Ohio Trust Warrants | — | — | — | — | 721 | — | 721 |
| Issuance of common stock in public offering, net of issuance costs of $6.5 million | 18,348,624 | 183 | — | — | 93,305 | — | 93,488 |
| Sale of common stock through at-the-market offerings, net of issuance costs | 2,838,894 | 28 | — | — | 24,089 | — | 24,117 |
| Net loss | — | — | — | — | — | (47,766) | (47,766) |
| Balance, June 30, 2026 | 76,240,884 | $761 | (122,608) | $(448) | $403,970 | $(278,153) | $126,130 |
| COMMON STOCK · TREASURY STOCK · ADDITIONALPAID-IN · ACCUMULATED · STOCKHOLDERS’ | |||||||
| SHARES | AMOUNT | SHARES | AMOUNT | CAPITAL | DEFICIT | EQUITY | |
| Balance, March 31, 2026 | 73,380,472 | $733 | (122,608) | $(448) | $376,992 | $(239,248) | $138,029 |
| Options exercised | 21,518 | — | — | — | 31 | — | 31 |
| Stock-based compensation | — | — | — | — | 2,010 | — | 2,010 |
| Change in fair value of NC Ohio Trust Warrants | — | — | — | — | 848 | — | 848 |
| Sale of common stock through at-the-market offerings, net of issuance costs | 2,838,894 | 28 | — | — | 24,089 | — | 24,117 |
| Net loss | — | — | — | — | — | (38,905) | (38,905) |
| Balance, June 30, 2026 | 76,240,884 | $761 | (122,608) | $(448) | $403,970 | $(278,153) | $126,130 |
| COMMON STOCK · TREASURY STOCK · ADDITIONALPAID-IN · ACCUMULATED · STOCKHOLDERS’ | |||||||
|---|---|---|---|---|---|---|---|
| SHARES | AMOUNT | SHARES | AMOUNT | CAPITAL | DEFICIT | EQUITY | |
| Balance, December 31, 2024 | 46,933,088 | $469 | (122,608) | $(448) | $258,511 | $(192,205) | $66,327 |
| Options exercised | 211,141 | 2 | — | — | 490 | — | 492 |
| Stock-based compensation | — | — | — | — | 1,947 | — | 1,947 |
| Restricted stock unit vesting | 330,779 | 3 | — | — | (3) | — | — |
| Change in fair value of NC Ohio Trust Warrants | — | — | — | — | (583) | — | (583) |
| Sale of common stock through at-the-market offerings, net of issuance costs | 987,772 | 10 | — | — | 5,028 | — | 5,038 |
| Exercise of pre-funded warrants | 3,328,064 | 33 | — | — | (33) | — | — |
| Issuance costs related to common stock and accompanying pre-funded warrants in public offering | — | — | — | — | 75 | — | 75 |
| Issuance of common stock in registered direct offering, net of issuance costs of $0.7 million | 3,221,395 | 32 | — | — | 14,299 | — | 14,331 |
| Net income | — | — | — | — | — | 2,583 | 2,583 |
| Balance, June 30, 2025 | 55,012,239 | $549 | (122,608) | $(448) | $279,731 | $(189,622) | $90,210 |
| COMMON STOCK · TREASURY STOCK · ADDITIONALPAID-IN · ACCUMULATED · STOCKHOLDERS’ | |||||||
| SHARES | AMOUNT | SHARES | AMOUNT | CAPITAL | DEFICIT | EQUITY | |
| Balance, March 31, 2025 | 49,369,749 | $493 | (122,608) | $(448) | $259,456 | $(184,826) | $74,675 |
| Options exercised | 92,785 | 1 | — | — | 244 | — | 245 |
| Stock-based compensation | — | — | — | — | 1,149 | — | 1,149 |
| Change in fair value of NC Ohio Trust Warrants | — | — | — | — | (99) | — | (99) |
| Sale of common stock through at-the-market offerings, net of issuance costs | 947,438 | 9 | — | — | 4,646 | — | 4,655 |
| Exercise of pre-funded warrants | 1,380,872 | 14 | — | — | (14) | — | — |
| Issuance costs related to common stock and accompanying pre-funded warrants in public offering | — | — | — | — | 50 | — | 50 |
| Issuance of common stock in registered direct offering, net of issuance costs of $0.7 million | 3,221,395 | 32 | — | — | 14,299 | — | 14,331 |
| Net loss | — | — | — | — | — | (4,796) | (4,796) |
| Balance, June 30, 2025 | 55,012,239 | $549 | (122,608) | $(448) | $279,731 | $(189,622) | $90,210 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.